U.S. markets open in 7 hours 1 minute
  • S&P Futures

    4,036.75
    +1.00 (+0.02%)
     
  • Dow Futures

    32,759.00
    -15.00 (-0.05%)
     
  • Nasdaq Futures

    12,868.25
    +1.00 (+0.01%)
     
  • Russell 2000 Futures

    1,795.10
    +1.80 (+0.10%)
     
  • Crude Oil

    69.50
    +0.17 (+0.25%)
     
  • Gold

    1,943.10
    +2.00 (+0.10%)
     
  • Silver

    22.52
    +0.10 (+0.42%)
     
  • EUR/USD

    1.0775
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.6060
    0.0000 (0.00%)
     
  • Vix

    21.38
    -2.77 (-11.47%)
     
  • GBP/USD

    1.2229
    +0.0010 (+0.08%)
     
  • USD/JPY

    132.4090
    -0.0510 (-0.04%)
     
  • Bitcoin USD

    28,240.78
    +480.82 (+1.73%)
     
  • CMC Crypto 200

    616.35
    +11.30 (+1.87%)
     
  • FTSE 100

    7,536.22
    +132.37 (+1.79%)
     
  • Nikkei 225

    27,466.61
    +520.94 (+1.93%)
     

Galapagos shares down after announcing clinical-trial miss for Crohn’s disease

Galapagos shares down after announcing clinical-trial miss for Crohn’s disease

U.S.-listed shares of Galapagos (GLPG) were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn’s disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. Galapagos plans to initiate a Phase 3 trial this year evaluating filgotinib as a treatment for AxSpA, a type of arthritis.